Summary
Boston Scientific Corporation's (BSX) 2007 10-K filing reveals a year of significant strategic restructuring, marked by sales of non-core businesses and a focus on optimizing operations. Despite a reported net loss of $495 million, the company's net sales grew 7% to $8.36 billion, largely driven by the acquisition of Guidant Corporation, which bolstered its Cardiac Rhythm Management (CRM) segment. However, sales in the crucial coronary stent business saw a notable decline of 19%, primarily due to market concerns surrounding late stent thrombosis and decreased procedural volumes. The company is actively managing its debt, which stood at $8.19 billion at year-end 2007, and is implementing cost-reduction initiatives aimed at improving financial performance and focusing on core growth areas. The company's strategic initiatives included divesting five non-strategic businesses, leading to approximately 2,000 job reductions. These actions are intended to streamline operations and improve financial flexibility. Despite the reported net loss, the company's operational cash flow remained positive at $934 million, and it continues to invest in research and development, albeit with a strategic realignment to focus on key product lines like drug-eluting stents and CRM technologies. Management is focused on navigating the challenges in the drug-eluting stent market and rebuilding confidence in its CRM offerings while working to resolve outstanding FDA matters.
Financial Highlights
27 data points| Revenue | $8.36B |
| Cost of Revenue | $2.34B |
| Gross Profit | $6.01B |
| SG&A Expenses | $2.91B |
| Operating Expenses | $6.03B |
| Operating Income | -$14.00M |
| Interest Expense | $570.00M |
| Net Income | -$495.00M |
| EPS (Basic) | $-0.33 |
| EPS (Diluted) | $-0.33 |
| Shares Outstanding (Basic) | 1.49B |
| Shares Outstanding (Diluted) | 1.49B |
Key Highlights
- 1Net sales increased by 7% to $8.36 billion in 2007, primarily driven by the inclusion of Guidant Corporation's results.
- 2The company reported a net loss of $495 million in 2007, compared to a net loss of $3.577 billion in 2006.
- 3Coronary stent sales decreased by 19% to $2.03 billion, significantly impacted by market concerns regarding drug-eluting stent safety and a declining market size.
- 4Cardiac Rhythm Management (CRM) sales increased by 55% to $2.12 billion, reflecting the full year inclusion of Guidant's operations.
- 5Boston Scientific initiated significant restructuring and cost-reduction measures, including the sale of five non-strategic businesses and approximately 2,300 job reductions.
- 6Total debt stood at $8.19 billion at year-end 2007, with the company actively working to reduce its debt obligations.
- 7Cash flow from operations was $934 million in 2007, down from $1.845 billion in 2006.
- 8The company is addressing FDA warning letters related to quality systems, with reinspections underway, which have impacted product launch schedules.